Christine Ann Fox net worth and biography

Christine Fox Biography and Net Worth

Christine is our Chief Financial Officer. She is a Certified Public Accountant (CPA) with over 20 years of experience in financial operations & reporting, technical accounting, and external audit.

Prior to joining Mereo, Christine served as Group Financial Controller and Treasurer of Travelport, an international B2B platform company, where she managed a global financial operations team. Previously, Christine spent more than 10 years at KPMG in the U.S. and Switzerland, in positions of increasing responsibility, primarily focused on large multi-national clients reporting under U.S. GAAP and IFRS across a wide variety of industries, including the pharmaceutical & biotech industries.

Ms. Fox received her B.Sc. in Accounting from Butler University, Indianapolis, USA.

What is Christine Ann Fox's net worth?: The estimated net worth of Christine Ann Fox is at least $221.22 thousand as of September 12th, 2024. Fox owns 108,443 shares of Mereo BioPharma Group stock worth more than $221,224 as of December 5th. This net worth approximation does not reflect any other investments that Fox may own. Additionally, Fox receives an annual salary of $569,770.00 as CFO at Mereo BioPharma Group. Learn More about Christine Ann Fox's net worth.
How old is Christine Ann Fox?: Fox is currently 43 years old. There are 7 older executives and no younger executives at Mereo BioPharma Group. The oldest executive at Mereo BioPharma Group is Dr. John A. Lewicki Ph.D., Chief Scientific Officer, who is 72 years old. Learn More on Christine Ann Fox's age.
What is Christine Ann Fox's salary?: As the CFO of Mereo BioPharma Group plc - Sponsored ADR, Fox earns $569,770.00 per year. There are 2 executives that earn more than Fox. The highest earning executive at Mereo BioPharma Group is Dr. Denise Vera Scots-Knight Ph.D., Co-Founder, CEO & Executive Director, who commands a salary of $890,560.00 per year. Learn More on Christine Ann Fox's salary.
How do I contact Christine Ann Fox?: The corporate mailing address for Fox and other Mereo BioPharma Group executives is ONE CAVENDISH PLACE FOURTH FLOOR, LONDON X0, W1G0QF. Mereo BioPharma Group can also be reached via phone at 44-33-3023-7300 and via email at [email protected]. Learn More on Christine Ann Fox's contact information.
Has Christine Ann Fox been buying or selling shares of Mereo BioPharma Group?: Christine Ann Fox has not been actively trading shares of Mereo BioPharma Group during the last ninety days. Most recently, Christine Ann Fox sold 9,128 shares of the business's stock in a transaction on Thursday, September 12th. The shares were sold at an average price of $4.47, for a transaction totalling $40,802.16. Following the completion of the sale, the chief financial officer now directly owns 108,443 shares of the company's stock, valued at $484,740.21. Learn More on Christine Ann Fox's trading history.
Who are Mereo BioPharma Group's active insiders?: Mereo BioPharma Group's insider roster includes Christine Fox (CFO), Alexandra Hughes-Wilson (Insider), John Lewicki (Insider), Deepika Pakianathan (Director), Denise Scots-Knight (CEO), and Charles Sermon (General Counsel). Learn More on Mereo BioPharma Group's active insiders.

Christine Ann Fox Insider Trading History at Mereo BioPharma Group

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction	Details
9/12/2024	Sell	9,128	$4.47	$40,802.16	108,443
6/25/2024	Sell	12,990	$3.69	$47,933.10	87,010

Christine Ann Fox Buying and Selling Activity at Mereo BioPharma Group

Mereo BioPharma Group Company Overview

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 MAP kinase inhibitor that is in Phase II clinical trials to treat acute exacerbations of chronic obstructive pulmonary disease; and Leflutrozole (BGS-649), an oral aromatase inhibitor for the treatment of hypogonadotropic hypogonadism which is in Phase 2 trials. In addition, it develops rare disease product candidates, including Setrusumab (BPS-804), an antibody for the treatment of osteogenesis imperfecta; and Alvelestat (MPH-966), an oral small molecule that is in Phase II clinical trial to treat Alpha-1 anti-trypsin deficiency. The company has a license agreement with Feng Biosciences for the development and commercialization of navicixizumab; license agreement with ReproNovo for the development and commercialization of leflutrozole; licensing agreement with AstraZeneca; and license agreement with Ultragenyx Pharmaceutical Inc. to develop and commercialize setrusumab. Mereo BioPharma Group plc was incorporated in 2015 and is headquartered in London, the United Kingdom.

Today's Range

Now: $2.04

$1.90

$2.06

50 Day Range

MA: $1.92

$1.75

$2.24

2 Week Range

Now: $2.04

$1.47

$3.94

Volume

2,428,717 shs

Average Volume

1,837,555 shs

Market Capitalization

$324.63 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.44

Christine Fox Biography and Net Worth

What is Christine Ann Fox's net worth?

How old is Christine Ann Fox?

What is Christine Ann Fox's salary?

How do I contact Christine Ann Fox?

Has Christine Ann Fox been buying or selling shares of Mereo BioPharma Group?

Who are Mereo BioPharma Group's active insiders?